Longevity Medical Institute says stem cells eased knee osteoarthritis pain at 12 months

Longevity Medical Institute published a peer-reviewed meta-analysis in Stem Cell Research International that found umbilical cord-derived stem cell injections were linked to better pain and function outcomes for knee osteoarthritis than steroid or hyaluronic acid injections at 12 months. The review adds controlled-trial evidence to a field still seeking longer-lasting nonsurgical options.

Why it matters: - Knee osteoarthritis affects hundreds of millions of people worldwide and is a leading cause of chronic pain, disability and reduced mobility. - Current nonsurgical injections, including corticosteroids and hyaluronic acid, often provide only temporary relief. - The findings add to the evidence base for regenerative medicine approaches that aim to deliver longer-lasting symptom improvement.

What happened: - Physicians and scientists from Longevity Medical Institute published a peer-reviewed systematic review and meta-analysis on allogeneic umbilical cord-derived stem cell therapy for knee osteoarthritis. - The study appeared in Stem Cell Research International under the title, "Allogeneic Umbilical Cord Mesenchymal Stromal Cells for Knee Osteoarthritis: Systematic Review and Meta-Analysis of Controlled Injection Trials." - The publication date was July 10, 2026. - The review compared stem cell injections with established injection therapies used for knee osteoarthritis.

The details: - The analysis used controlled human clinical trials and a random-effects meta-analysis. - The pooled results showed lower WOMAC pain scores at 12 months for stem cell therapy versus active comparator injections. - The direction of benefit was consistent in studies using hyaluronic acid and corticosteroid comparators. - The review also found lower total WOMAC scores at 12 months, pointing to broader improvements in pain, stiffness and physical function. - The quantitative analysis included two controlled clinical trials. - One trial compared repeated stem cell therapy with hyaluronic acid. - Another randomized controlled trial compared stem cell therapy with intra-articular triamcinolone corticosteroid. - The review followed PRISMA 2020 reporting standards. - The authors focused exclusively on controlled human clinical trials comparing umbilical cord-derived stem cell therapy with active injection comparators. - No clear signal of severe treatment-related adverse events was identified in the controlled studies included in the quantitative analysis. - An additional Phase I study in the qualitative review supported feasibility and tolerability of repeated stem cell administration. - The authors said larger controlled trials are still needed to define long-term safety and optimal dosing. - The publication is available through Stem Cell Research International. The DOI is 10.33140/SCRI.10.01.05.

Between the lines: - The review is notable because it goes beyond a narrative summary and uses predefined methods to pool controlled trial data. - The benefit signal held across two different comparator therapies, which suggests the result was not limited to a single injection type. - The evidence base remains small, so the findings are encouraging but not definitive. - The article positions Longevity Medical Institute’s research program as focused on regenerative medicine, stem cell science and evidence-based longevity medicine.

What's next: - The authors said larger randomized controlled trials are needed. - Future studies will need to better measure durability, long-term safety and dosing strategy. - The findings are likely to keep umbilical cord-derived stem cell therapy under investigation as a possible treatment option for knee osteoarthritis.

The bottom line: - The meta-analysis found controlled-trial evidence that umbilical cord-derived stem cell therapy may offer more durable 12-month pain and function benefits for knee osteoarthritis than common injection-based comparators, but the field still needs larger trials before drawing firm conclusions.